Notice Type
Notice Title

Corrigendum—Consent to the Distribution of New Medicines

In the notice with the above heading, published in the New Zealand Gazette, 21 March 2019, Notice No. 2019-go1220, replace the entry for NYXOID with the following:


Active Ingredient:
Dosage Form:
New Zealand Sponsor:

Naloxone hydrochloride dihydrate 2.2mg equivalent to naloxone 1.8mg per 100mcL
Nasal spray solution
Mundipharma New Zealand Limited
Summit Biosciences LLC, Kentucky, United States of America

Dated this 25th day of March 2019.

CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).